On March 15, 2018 Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, reported that results from two preclinical studies highlighting the potential benefits of fractionated dosing regimens of CLR 131 and the ability of the company’s phospholipid drug conjugates (PDCs) to provide improved targeting of tumor cells have been selected for late-breaking poster presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2018 (AACR 2018), April 14-18, 2018 in Chicago (Press release, Cellectar Biosciences, MAR 15, 2018, View Source [SID1234524807]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The following research will be presented:
Poster Title: Phospholipid drug conjugates show specificity for a broad range of tumor cells and provides a novel approach for targeted or precision therapy
Poster Number: 10957
Session Title: Late-Breaking Research: Cancer Chemistry
Session Date and Time: Monday, April 16, 2018, 8:00 am – 12:00 pm (CT)
Session Location: Poster Section 43
Presenter: Jarrod Longcor, chief business officer of Cellectar Biosciences
Poster Title: Efficacy of fractionated injections of CLR 131 in an OPM-2 SCID nude mouse model
Poster Number: 10770
Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 3
Session Date and Time: Tuesday, April 17, 2018 1:00 pm – 5:00 pm (CT)
Session Location: Poster Section 43
Presenter: Jarrod Longcor, chief business officer of Cellectar Biosciences
CLR 131 is Cellectar’s investigational radioiodinated PDC therapy that exploits the tumor-targeting properties of the company’s proprietary phospholipid ether (PLE) and PLE analogs to selectively deliver radiation to malignant tumor cells, thus minimizing radiation exposure to normal tissues. Poster 10770 compares bolus dosing to fractionated dosing of CLR 131 in a preclinical mouse model.
Various PDC molecules have been shown to provide specificity in targeting tumor cells versus normal cells both in vitro and in vivo irrespective of the payload. Poster 10957 will further elaborate upon the mechanism of targeting and uptake as well as the cellular trafficking of these molecules.
"Over the past year, we have greatly enhanced our understanding of both our lead asset CLR 131, and our proprietary delivery platform," said James Caruso, chief executive officer of Cellectar Biosciences. "Our data suggest a more optimized dosing scheme that we have recently incorporated into our current Phase 1 trial and also speak to the broad potential of the delivery technology itself."